Farmavita.Net is network for pharmaceutical licensing and regulatory affairs. http://www.farmavita.net Wed, 17 Mar 2010 23:48:27 +0100 FeedCreator 1.7.2 http://www.farmavita.net/images/M_images/rss20.gif http://www.farmavita.net Farmavita.Net is network for pharmaceutical licensing and regulatory affairs. http://www.farmavita.net/content/view/1395/84/ Big pharma struggles to benefit from increased CVD drug usage London - Pharmaceutical companies will struggle to profit from the cardiovascular disease (CVD) market over the next decade despite growing drug usage, according to Datamonitor. New research* by the independent business analyst predicts that the CVD pharma market will grow from $99bn in 2008 to $107bn in 2018. Patent expiries and generic competition will have a major impact and Datamonitor expects AstraZeneca and Novo Nordisk to emerge as the only major CVD pharma companies to generate positive sales growth over the period. Business News - Press Release Mon, 15 Mar 2010 12:42:58 +0100 http://www.farmavita.net/content/view/1394/84/ First Pharma CRM application for iPhone in the world Fast, simple, functional and revolutionary! Sales Vision iTouch is comming soon on the market and it is about first Pharma CRM application that supports the work on iPhone globally. Lately there were rumors that were are preparing a new version of Sales Vision on iPhone - and it`s finally here! We are proudly announcing that our region has finally gotten a competive CRM application for iPhone. Business News - Press Release Fri, 12 Mar 2010 16:05:46 +0100 http://www.farmavita.net/content/view/1389/120/ Lacerta BioCapital Lacerta BioCapital, a member of Farmavita.Net, invests in sound, stable companies in promising Life Science segments with attractive futures (e.g., sustained positive cash flow; value increase potential of at least 20% p.a.; growth potential either organically or through acquisition; etc.). Our target companies have a sound customer base with a well balanced product portfolio. We aim to have a total investment budget of approximately €300 million (including credit capital), to be invested in around 10-15 Life Science companies. Please contact us for introduction to Lacerta BioCapital. Business News - Business for Sale Thu, 25 Feb 2010 12:06:56 +0100 http://www.farmavita.net/content/view/1368/57/ Our company offers probiotics in sachets or capsules in any concentration and containing any strains. We are very competitive in terms of prices and we are very flexible in terms of minimum batch. Pharma Out-Licensing - OTC / Nutraceutical - Offer Fri, 12 Feb 2010 16:48:31 +0100 http://www.farmavita.net/content/view/1338/84/ Diclofenac 1% Gel Member of Farmavita.Net team is looking for EU-CTD Dossier with supply for Diclofenac 1% Gel 50 mg for Italian Market. The Dossier should also contain full clinical studies. Pharma In-Licensing - License-in Demand Thu, 04 Feb 2010 10:36:30 +0100 http://www.farmavita.net/content/view/1316/84/ US Surgical Sutures Market: Surgical Procedures Growth to Drive Demand GlobalData's US Surgical Sutures Market: Surgical Procedures Growth to Drive Demand report is an essential source of data and analysis on the US surgical sutures market with complete coverage by categories. The report provides market landscape, competitive landscape and market trends information on two market categories - absorbable sutures and non absorbable sutures. The report identifies the key trends shaping and driving the dynamism in the US surgical sutures market. The report also provides insight on the prevalent competitive landscape and on the emerging players which are expected to bring significant shift in the market standing of the existing leaders. The report also provides valuable insight on the pipeline products within the US surgical sutures market. Claim 10% Discount for Farmavita.Net Members when purchasing this report! Business Reports - Market Report Thu, 14 Jan 2010 10:36:44 +0100 http://www.farmavita.net/content/view/1315/84/ Seeking: Novel new sensations and materials for lip products A kiss may be just a kiss, but we're looking for unique materials to add to lip products for new lip sensations and experiences (such as cooling, warming, numbing, tingling and flavors), solutions that can impart prolonged sensate experiences, and solutions that can impart not-yet-known sensations. Pharma In-Licensing - Innovative Medicine Demand Mon, 11 Jan 2010 21:59:54 +0100 http://www.farmavita.net/content/view/1303/57/ Development-stage pain products The Company seeks to divest its development-stage pain products MGX-001 (extended release morphine combined with an atypical stimulant) and MGX-002 (a follow-on opioid combined with an atypical stimulant). These products are expected to significantly reduce commonly-experienced side effects versus existing opiate therapies. Pharma Out-Licensing - Innovative Medicines Offer Tue, 15 Dec 2009 23:21:58 +0100 http://www.farmavita.net/content/view/1298/84/ Bacteria strains and fermentation technologies Farmavita.Net member is seeking bacteria strains and fermentation technologies to produce the following products Lycopene, Chlortetracycline and Acetylisovaleryltylosin. Pharma In-Licensing - API/Technology Demand Fri, 11 Dec 2009 13:12:33 +0100 http://www.farmavita.net/content/view/1289/84/ Mapping the Healthcare Landscape: Bringing pharmaceuticals into focus Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the anticipated revenue short-fall, with diversification away from pharmaceuticals into other healthcare sectors one avenue under consideration. Claim 10% Discount for Farmavita.Net Members when purchasing this report! Business Reports - Forecast Thu, 03 Dec 2009 09:51:58 +0100 http://www.farmavita.net/content/view/1275/57/ Innovatve topical for Psoriasis We are interested in Co- development of an innovative topical formulation presented in a delivery system particularly targeted for treatment of Psoriasis and other dermatoses of hyperkeratotic nature. The formulation comprises of ingredients having anti inflammatory and a keratosolvent properties. The innovative formulation presented in a specially designed delivery system is patent potential and has superior clinical efficacy as compared to topical keratolytics such as Salicylic Acid, coal tar and synthetic retinoids. Pharma Out-Licensing - Innovative Medicines Offer Thu, 29 Oct 2009 16:00:29 +0100 http://www.farmavita.net/content/view/1270/84/ Pharma To Market provides global regulatory support services and outsourcing solutions to the pharmaceutical industry. Based in Australia, we are unique in that we offer regulatory and technical support for submissions in key global markets including Australia, New Zealand, USA, Europe, Canada, and South East Asia. Pharma To Market are licensed vendors of the Regulatory Solutions Suite (RSS) of software from ISI. We offer full implementation and maintenance services to companies in Australia and New Zealand for ISI's Regulatory Solutions Suite including eCTDXPress, ISIWriter, ISIToolBox and ISIPublisher. Pharma To Market also offer complete outsourcing solutions for eCTD and paper publishing. Partners - Consultants Wed, 14 Oct 2009 13:23:16 +0100 http://www.farmavita.net/content/view/1259/84/ Biotech in the New EU Member States: Policy Recommendations The study carried-out on the development status and capacity of healthcare biotechnology in the new EU Member States and candidate countries shows a much contrasted picture of biotechnology development in this region. Each country has a different economic development strategy and a unique history and capacity in the life-science and healthcare sector which determines its path to development. Based on these observations, it would be unsuitable to propose general recommendations in a sort of unique formula to build or develop a healthy healthcare biotechnology sector. Donwnload free 14 pages report at our Download (http://www.farmavita.net/component/option,com_remository/Itemid,88/func,fileinfo/id,105/) Section. Business Reports - Forecast Mon, 28 Sep 2009 11:54:42 +0100 http://www.farmavita.net/content/view/1258/84/ Biotech in the New EU Member States: an Emerging Sector This report is the first of its kind to try and understand the state of the biotechnology industry in the new Member States and candidate countries. As with any bottom-up work, it took a lot of effort and persistence to gather data on current and prospective developments in this area. Our goal was to strengthen the understanding of the European biotechnology scene and we believe that with the knowledge accumulated we have reached this goal. This report should enable policy makers and investors to make informed decisions about biotechnology support and development. The databases developed during this project will also provide better international visibility to the companies, which could lead to new cooperation or investment. Donwnload free 33 pages report at our Download (http://www.farmavita.net/component/option,com_remository/Itemid,88/func,fileinfo/id,104/) Section. Business Reports - Forecast Mon, 28 Sep 2009 10:40:23 +0100 http://www.farmavita.net/content/view/1232/84/ I am looking for the competent technology offer for CEFUROXIME ACID. If any one is interested to fell cefuroxime acid technology can contact me. - Dr Anand Handa Pharma In-Licensing - API/Technology Demand Tue, 15 Sep 2009 07:45:25 +0100